Detection of a novel panel of 24 genes with high frequencies of mutation in gastric cancer based on next-generation sequencing.
Gastric cancer
Microsatellite instability
Mutated genes
Next-generation sequencing
Target sites
Journal
World journal of clinical cases
ISSN: 2307-8960
Titre abrégé: World J Clin Cases
Pays: United States
ID NLM: 101618806
Informations de publication
Date de publication:
26 May 2022
26 May 2022
Historique:
received:
16
12
2021
revised:
06
02
2022
accepted:
26
03
2022
entrez:
8
7
2022
pubmed:
9
7
2022
medline:
9
7
2022
Statut:
ppublish
Résumé
Gastric cancer is a leading cause of cancer-related mortality worldwide. Many somatic mutations have been identified based on next-generation sequencing; they likely play a vital role in cancer treatment selection. However, next-generation sequencing has not been widely used to diagnose and treat gastric cancer in the clinic. To test the mutant gene frequency as a guide for molecular diagnosis and personalized therapy in gastric cancer by use of next-generation sequencing. We constructed a panel of 24 mutant genes to detect somatic nucleotide variations and copy number variations based on a next-generation sequencing technique. Our custom panel included high-mutation frequency cancer driver and tumour suppressor genes. Mutated genes were also analyzed using the cBioPortal database. The clinical annotation of important variant mutation sites was evaluated in the ClinVar database. We searched for candidate drugs for targeted therapy and immunotherapy from the OncoKB database. In our study, the top 16 frequently mutated genes were TP53(58%), ERBB2(28%), BRCA2 (23%), NF1 (19%), PIK3CA (14%), ATR (14%), MSH2 (12%), FBXW7 (12%), BMPR1A (12%), ERBB3 (11%), ATM (9%), FGFR2 (8%), MET (8%), PTEN (6%), CHD4 (6%), and KRAS (5%). TP53 is a commonly mutated gene in gastric cancer and has a similar frequency to that in the cBioPortal database. 33 gastric cancer patients (51.6%) with microsatellite stability and eight patients (12.5%) with microsatellite instability-high were investigated. Enrichment analyses demonstrated that high-frequency mutated genes had transmembrane receptor protein kinase activity. We discovered that BRCA2, PIK3CA, and FGFR2 gene mutations represent promising biomarkers in gastric cancer. We developed a powerful panel of 24 genes with high frequencies of mutation that could detect common somatic mutations. The observed mutations provide potential targets for the clinical treatment of gastric cancer.
Sections du résumé
BACKGROUND
BACKGROUND
Gastric cancer is a leading cause of cancer-related mortality worldwide. Many somatic mutations have been identified based on next-generation sequencing; they likely play a vital role in cancer treatment selection. However, next-generation sequencing has not been widely used to diagnose and treat gastric cancer in the clinic.
AIM
OBJECTIVE
To test the mutant gene frequency as a guide for molecular diagnosis and personalized therapy in gastric cancer by use of next-generation sequencing.
METHODS
METHODS
We constructed a panel of 24 mutant genes to detect somatic nucleotide variations and copy number variations based on a next-generation sequencing technique. Our custom panel included high-mutation frequency cancer driver and tumour suppressor genes. Mutated genes were also analyzed using the cBioPortal database. The clinical annotation of important variant mutation sites was evaluated in the ClinVar database. We searched for candidate drugs for targeted therapy and immunotherapy from the OncoKB database.
RESULTS
RESULTS
In our study, the top 16 frequently mutated genes were TP53(58%), ERBB2(28%), BRCA2 (23%), NF1 (19%), PIK3CA (14%), ATR (14%), MSH2 (12%), FBXW7 (12%), BMPR1A (12%), ERBB3 (11%), ATM (9%), FGFR2 (8%), MET (8%), PTEN (6%), CHD4 (6%), and KRAS (5%). TP53 is a commonly mutated gene in gastric cancer and has a similar frequency to that in the cBioPortal database. 33 gastric cancer patients (51.6%) with microsatellite stability and eight patients (12.5%) with microsatellite instability-high were investigated. Enrichment analyses demonstrated that high-frequency mutated genes had transmembrane receptor protein kinase activity. We discovered that BRCA2, PIK3CA, and FGFR2 gene mutations represent promising biomarkers in gastric cancer.
CONCLUSION
CONCLUSIONS
We developed a powerful panel of 24 genes with high frequencies of mutation that could detect common somatic mutations. The observed mutations provide potential targets for the clinical treatment of gastric cancer.
Identifiants
pubmed: 35801059
doi: 10.12998/wjcc.v10.i15.4761
pmc: PMC9198883
doi:
Types de publication
Journal Article
Langues
eng
Pagination
4761-4775Informations de copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: The authors declare that they have no competing interests.
Références
JAMA Oncol. 2020 Oct 1;6(10):1571-1580
pubmed: 32880601
Nat Med. 2015 May;21(5):449-56
pubmed: 25894828
Br J Cancer. 2014 Feb 18;110(4):967-75
pubmed: 24457912
Nature. 2019 Jul;571(7766):576-579
pubmed: 31292550
Clin Cancer Res. 2019 Apr 1;25(7):2033-2041
pubmed: 30442682
J Cancer. 2019 Jan 1;10(1):20-27
pubmed: 30662521
Nat Biotechnol. 2021 Sep;39(9):1141-1150
pubmed: 34504346
Cold Spring Harb Perspect Med. 2016 Aug 01;6(8):
pubmed: 27329033
J Clin Oncol. 2020 Jul 20;38(21):2418-2426
pubmed: 32167861
Nat Med. 1996 Jan;2(1):72-9
pubmed: 8564846
Sci Rep. 2020 Mar 24;10(1):5270
pubmed: 32210254
Ann Oncol. 2020 Nov;31(11):1491-1505
pubmed: 32853681
Nature. 2014 Sep 11;513(7517):202-9
pubmed: 25079317
Am J Pathol. 2017 Oct;187(10):2133-2138
pubmed: 28734944
World J Gastroenterol. 2018 Jul 14;24(26):2818-2832
pubmed: 30018477
Cancer Sci. 2019 Nov;110(11):3405-3414
pubmed: 31495054
JAMA Oncol. 2017 Sep 01;3(9):1197-1203
pubmed: 28241187
Mol Cancer. 2020 Oct 30;19(1):154
pubmed: 33126883
J Cancer. 2019 Jan 29;10(4):821-828
pubmed: 30854087
Hum Genomics. 2017 Jun 21;11(1):13
pubmed: 28637487
Cancer Discov. 2019 Oct;9(10):1388-1405
pubmed: 31315834
Cancer Commun (Lond). 2020 May;40(5):205-210
pubmed: 32359212
Cancer Cell. 2017 Jun 12;31(6):820-832.e3
pubmed: 28528867
JAMA Oncol. 2021 Apr 01;7(4):573-584
pubmed: 33480963
Gastroenterology. 2020 Jul;159(1):335-349.e15
pubmed: 32247694
Am J Gastroenterol. 2015 Feb;110(2):223-62; quiz 263
pubmed: 25645574
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Clin Gastroenterol Hepatol. 2020 Mar;18(3):534-542
pubmed: 31362118
Nat Rev Clin Oncol. 2018 Jan;15(1):13-30
pubmed: 28948977
Oncotarget. 2017 Nov 30;8(69):114371-114392
pubmed: 29371993
Oncotarget. 2017 Aug 3;8(47):82910-82919
pubmed: 29137312
IEEE/ACM Trans Comput Biol Bioinform. 2019 Sep-Oct;16(5):1693-1701
pubmed: 29994072
J Immunother Cancer. 2020 Mar;8(1):
pubmed: 32238472
Sci Rep. 2018 Aug 23;8(1):12671
pubmed: 30140002
Science. 2017 Jul 28;357(6349):409-413
pubmed: 28596308
Pathobiology. 2020;87(6):367-374
pubmed: 33161400
Future Oncol. 2021 Feb;17(5):491-501
pubmed: 33167735
Int J Clin Exp Med. 2015 Jul 15;8(7):11692-700
pubmed: 26380006